Press release content from Business Wire. The AP news staff was not involved in its creation.
Elanco Achieves Important Innovation Milestones, Momentum to Start 2021
February 19, 2021 GMT
GREENFIELD, Ind. (BUSINESS WIRE) Feb 19, 2021
Elanco Animal Health Incorporated (NYSE: ELAN) today announces four important innovation milestones, including two product approvals, amid a string of recent progress on its innovation commitments.
Farm Animal
Yesterday, the U.S. FDA approved Increxxa™ (tulathromycin injection) for the treatment of bovine respiratory disease (BRD) and swine respiratory disease (SRD).
Earlier this week, Health Canada approved Experior™ 50, (lubabegron), a new concentration of Experior for the reduction of ammonia gas emissions per kilogram of live weight and hot carcass weight during the last 14 to 91 days on feed, representing the first animal health product with proven environmental benefit.